Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-13Clinical Trial Update: Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating golcadomide in combination with nivolumab for patients with Non-Hodgkin lymphoma that is refractory af…
-
CLINICAL_TRIALS withdrawal · 2025-12-18Clinical Trial Update: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies [Phase 1]
A Phase 1 study of CNTY-101 in CD19-positive B-cell malignancies has been terminated.
-
CLINICAL_TRIALS withdrawal · 2025-08-08Clinical Trial Update: Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
The HY004 cell injection trial for relapsed or refractory B-cell non-Hodgkin lymphoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-06-12Clinical Trial Update: Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. [NA]
A clinical trial evaluating Triamcinolone acetonide injections with a novel needle-free delivery system for primary cutaneous lymphoma plaqu…
-
CLINICAL_TRIALS withdrawal · 2025-03-07Clinical Trial Update: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas [Phase 1]
A Phase 1 study of CG-806 in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and non-Hodgkin's lymphomas ha…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-02-25Clinical Trial Update: Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3) [Phase 1, Phase 2]
Dizal Pharmaceuticals has withdrawn the Phase 1/2 trial of the oral BTK inhibitor DZD9008 in non-Hodgkin lymphoma.
-
CLINICAL_TRIALS withdrawal · 2025-02-24Clinical Trial Update: QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL [Phase 1, Phase 2]
The QUILT-3.052 trial evaluating the NANT Non-Hodgkin Lymphoma Vaccine in relapsed CD20-positive NHL has been withdrawn (Phase 1/Phase 2).
-
CLINICAL_TRIALS withdrawal · 2024-10-24Clinical Trial Update: Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas [Phase 1, Phase 2]
Clinical trial evaluating FE 203799 in adults with lymphomas has been withdrawn. The study examined safety, tolerability, and PK/PD in Phase…
-
CLINICAL_TRIALS withdrawal · 2024-10-22Clinical Trial Update: (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). [Phase 1]
Phase 1 pediatric lymphoma trial evaluating pediTACTAL TAA-specific cytotoxic T-lymphocytes has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-10-03Clinical Trial Update: B-Cell Hematologic Malignancy Vaccination Registry
A clinical trial update indicates that the B-cell hematologic malignancy vaccination registry (NCT02298816) sponsored by Wake Forest Univers…
-
CLINICAL_TRIALS withdrawal · 2024-09-05Clinical Trial Update: A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma [Phase 1]
This clinical trial update indicates that Taiho Oncology’s Phase 1 dose-finding study followed by a safety and efficacy study in patients wi…
-
CLINICAL_TRIALS withdrawal · 2024-08-07Clinical Trial Update: Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP [NA]
Clinical trial update shows the Emesis Control Study in Non-Hodgkin lymphoma patients receiving R-CHOP has been withdrawn.
-
EMA withdrawal · 2024-07-10EMA Expired: Pixuvri (pixantrone dimaleate) — Les Laboratoires Servier
The EMA has expired the marketing authorization for Pixuvri (pixantrone dimaleate) by Les Laboratoires Servier, effectively withdrawing its …
-
CLINICAL_TRIALS withdrawal · 2024-07-08Clinical Trial Update: GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma [Phase 1, Phase 2]
The GEMHDM2014 trial evaluating Gem-HDM HDT and autologous stem cell transplant for relapsed/refractory lymphoma has been terminated after P…
-
CLINICAL_TRIALS withdrawal · 2023-04-21Clinical Trial Update: A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 3]
A Phase 3 trial combining Zilovertamab with Ibrutinib for relapsed or refractory mantle cell lymphoma has been withdrawn.
-
EMA withdrawal · 2021-08-16EMA Withdrawn: Ritemvia (rituximab) — Celltrion Healthcare Hungary Kft.
EMA withdrawal of Ritemvia (rituximab) by Celltrion Healthcare Hungary Kft., affecting indications in lymphoma (non-Hodgkin) and vasculitic …
-
CLINICAL_TRIALS withdrawal · 2020-10-05Clinical Trial Update: Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL [Phase 3]
A Phase 3 trial comparing fludarabine, pixantrone, and rituximab versus fludarabine and rituximab for relapsed or refractory indolent non-Ho…
-
EMA withdrawal · 2019-07-08EMA Withdrawn: Rituzena (previously Tuxella) (rituximab) — Celltrion Healthcare Hungary Kft.
EMA withdrew Rituzena (rituximab) from the market (formerly Tuxella), with the decision dated 28 January 2019.
-
CLINICAL_TRIALS withdrawal · 2018-04-05Clinical Trial Update: A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 study of atezolizumab in combination with an immunotherapy agent (with or without anti-CD20 therapy) for relapsed or refractory no…
-
CLINICAL_TRIALS withdrawal · 2017-11-29Clinical Trial Update: Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease [Phase 2]
Phase 2 trial evaluating specially treated stem cells for peripheral stem cell transplantation in patients with Non-Hodgkin lymphoma or Hodg…
-
CLINICAL_TRIALS withdrawal · 2017-06-27Clinical Trial Update: Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) [Phase 1, Phase 2]
The Phase 1/2 trial assessing pembrolizumab in combination with chemotherapy for advanced lymphoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-11-08Clinical Trial Update: Prospective Study of Lymphoproliferative Diseases
This clinical trial update notes that the prospective study of lymphoproliferative diseases sponsored by West Virginia University has been w…
-
CLINICAL_TRIALS withdrawal · 2016-11-01Clinical Trial Update: Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant [Phase 2]
A Phase II trial evaluating an EBV-derived dendritic cell vaccine in autologous stem cell transplantation for Hodgkin lymphoma and non-Hodgk…
-
CLINICAL_TRIALS withdrawal · 2016-10-14Clinical Trial Update: R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma [Phase 2]
A phase 2 trial of R-CHOP-B (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Bevacizumab) for diffuse large B-cell ly…
-
CLINICAL_TRIALS withdrawal · 2016-10-07Clinical Trial Update: Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma [Phase 1, Phase 2]
Withdrawal of a Phase 1/Phase 2 clinical trial evaluating the combination of 6-thioguanine and 6-mercaptopurine for maintenance therapy in c…